Onilcamotide
DRACPC ID DRACPC0099
Active Ingredients Onilcamotide
Description A cancer vaccine composed of an immunogenic peptide derived from the Ras homolog family member C (RhoC; Rho-related GTP-binding protein RhoC) that is emulsified in the immunoadjuvant montanide ISA-51, with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, onilcamotide may stimulate the host immune system to mount a humoral and cytotoxic T-lymphocyte (CTL) response against tumor cells expressing RhoC, which results in tumor cell lysis. RhoC, a tumor-associated antigen (TAA) that is overexpressed in a variety of tumor cell types, is associated with increased metastatic potential.
Synonyms RhoC Peptide Vaccine RV001V; RV001 Vaccine; RV001V; Onilcamotide
Type Biotech
Disease Prostate Cancer Recurrent
Classification
Peptide and derivative Vaccine
Structure Information
Molecular Formula C96H177N39O24S
Molecular Weight 2293.7
Active Sequence ATRAGLQVRKNKRRRGCPIL
Sequence Length 20
Modification None
Structure
IUPAC Name Not available
InChI Not available
InChI_Key Not available
SMILES Not available
External Codes
PubChem CID 155801574
DrugBank Accession Number Not available
NCI Thesaurus Code C151937
UNII UQE6KP7T0D GSRS
CAS 1164096-85-8
Drug approval
Drug indication
Investigated for use/treatment in Prostate Cancer Recurrent.
The drug is not approved.
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT04114825 | A Phase 2, Double-Blind, Placebo Controlled Study of RV001V in Men With Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer (BRaVac) | Prostate Cancer Recurrent | Phase 2 | Treatment |
| NCT03199872 | A Phase I/II Study of RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours | Prostate Cancer | Phase 1/2 | Treatment |
More clinical information is obtained from ClinicalTrials.gov.
